J. Newell-price, X. Bertagna, A. Grossman, and L. Nieman, Cushing's syndrome, The Lancet, vol.367, issue.9522, pp.1605-1617, 2006.
DOI : 10.1016/S0140-6736(06)68699-6

B. Biller, A. Grossman, P. Stewart, S. Melmed, X. Bertagna et al., Treatment of Adrenocorticotropin-Dependent Cushing???s Syndrome: A Consensus Statement, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.7, pp.2454-2462, 2008.
DOI : 10.1210/jc.2007-2734

R. Pivonello, D. Martino, M. , D. Leo, M. Lombardi et al., Cushing's Syndrome, Endocrinology and Metabolism Clinics of North America, vol.37, issue.1, pp.135-149, 2008.
DOI : 10.1016/j.ecl.2007.10.010

C. Data, N. Statistics, and . Iii, Available at, 2005.

R. Feelders, S. Pulgar, A. Kempel, and A. Pereira, MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects, European Journal of Endocrinology, vol.167, issue.3, pp.311-326, 2012.
DOI : 10.1530/EJE-11-1095

C. Bruns, I. Lewis, U. Briner, G. Meno-tetang, and G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, European Journal of Endocrinology, vol.146, issue.5, pp.707-716, 2002.
DOI : 10.1530/eje.0.1460707

D. Batista, X. Zhang, Y. Zhou, P. Ansell, R. Gejman et al., SOM230 inhibits cell proliferation in human corticotroph adenomas and in human pituitary tumor-derived PDFS cell line, 88th Annual Meeting of the Endocrine Society, pp.24-27, 2006.

L. Hofland, J. Van-der-hoek, R. Feelders, M. Van-aken, P. Van-koetsveld et al., The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5, European Journal of Endocrinology, vol.152, issue.4, pp.645-654, 2005.
DOI : 10.1530/eje.1.01876

A. Colao, S. Petersenn, J. Newell-price, J. Findling, F. Gu et al., A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease, New England Journal of Medicine, vol.366, issue.10, pp.914-924, 2012.
DOI : 10.1056/NEJMoa1105743

N. Pharma and A. , Signifor summary of product characteristics Available at: http://www.signifor.com/european-pro duct-characteristics.jsp (last accessed, 2012.

N. Pharma, A. Markkanen, H. Valimaki, M. Stenman, and U. , Signifor full prescribing information Available at Determination of urinary free cortisol by HPLC, Clin Chem, vol.43, pp.1386-1391, 1997.

A. Godbout, M. Manavela, K. Danilowicz, H. Beauregard, O. Bruno et al., Cabergoline monotherapy in the long-term treatment of Cushing's disease, European Journal of Endocrinology, vol.163, issue.5, pp.709-716, 2010.
DOI : 10.1530/EJE-10-0382

R. Pivonello, D. Martino, M. Cappabianca, P. , D. Leo et al., The Medical Treatment of Cushing???s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.1, pp.223-230, 2009.
DOI : 10.1210/jc.2008-1533

R. Pivonello, S. Petersenn, J. Newell-price, J. Findling, F. Gu et al., Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study, Clinical Endocrinology, vol.362, issue.Suppl 1, pp.408-417, 2014.
DOI : 10.1111/cen.12431

R. Pivonello, S. Petersenn, J. Newell-price, F. Gu, M. Maldonado et al., Pasireotide treatment is associated with improvements in hypertension: 12-month results from a large Phase III study in Cushing's disease, Endocr Abstr, vol.29, p.1406, 2012.

R. Henry, T. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-saylan et al., Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.8, pp.3446-3453, 2013.
DOI : 10.1210/jc.2013-1771